<DOC>
	<DOCNO>NCT01380730</DOCNO>
	<brief_summary>To evaluate effect 12 week subcutaneous ( SC ) evolocumab ( AMG 145 ) administer every 2 week ( Q2W ) every 4 week ( Q4W ) , compare placebo , percent change baseline LDL-C use addition statin adult hypercholesterolemia .</brief_summary>
	<brief_title>LAPLACE-TIMI 57 : Low-density Lipoprotein Cholesterol ( LDL-C ) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female ≥ 18 ≤ 80 year age On approved statin , without ezetimibe , stable dose ( ) least 4 week Fasting LDLC ≥ 85 mg/dL Fasting triglycerides ≤ 400 mg/dL Myocardial infarction , unstable angina , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) stroke within 3 month prior randomization Type 1 diabetes ; newly diagnose poorly control type 2 diabetes ( Glycosyated Hemoglobin ( HbA1c ) &gt; 8.5 % ) Uncontrolled hypertension New York Heart Association ( NYHA ) III IV heart failure , know leave ventricular ejection fraction &lt; 30 % Uncontrolled cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Proprotein convertase subtilisin/kexin type 9 ( PCSK9 )</keyword>
</DOC>